Brainstorm’s nurown phase 3 als clinical trial now fully enrolled

Brainstorm cell therapeutics inc. announced that it has fully enrolled the 200-patient phase 3 clinical trial evaluating repeat intrathecal administration of nurown cellular therapeutic (autologous msc-ntf cells) in als (amyotrophic lateral sclerosis). brainstorm’s phase 3 clinical trial is being conducted at the university of california, irvine; cedars-sinai medical center; california pacific medical center; massachusetts general hospital; university of massachusetts medical school; and the mayo clinic.
BCLI Ratings Summary
BCLI Quant Ranking